These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 25552368

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy.
    Fan X, Brezski RJ, Fa M, Deng H, Oberholtzer A, Gonzalez A, Dubinsky WP, Strohl WR, Jordan RE, Zhang N, An Z.
    Breast Cancer Res; 2012 Aug 08; 14(4):R116. PubMed ID: 22873525
    [Abstract] [Full Text] [Related]

  • 4. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.
    Brezski RJ, Kinder M, Grugan KD, Soring KL, Carton J, Greenplate AR, Petley T, Capaldi D, Brosnan K, Emmell E, Watson S, Jordan RE.
    MAbs; 2014 Aug 08; 6(5):1265-73. PubMed ID: 25517311
    [Abstract] [Full Text] [Related]

  • 5. The Proteolytic Cleavage of Therapeutic Monoclonal Antibody Hinge Region: More Than a Matter of Subclass.
    Deveuve Q, Lajoie L, Barrault B, Thibault G.
    Front Immunol; 2020 Aug 08; 11():168. PubMed ID: 32117299
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Enzymatic Inactivation of Endogenous IgG by IdeS Enhances Therapeutic Antibody Efficacy.
    Järnum S, Runström A, Bockermann R, Winstedt L, Crispin M, Kjellman C.
    Mol Cancer Ther; 2017 Sep 08; 16(9):1887-1897. PubMed ID: 28533435
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
    Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA.
    Semin Oncol; 1999 Aug 08; 26(4 Suppl 12):60-70. PubMed ID: 10482195
    [Abstract] [Full Text] [Related]

  • 14. Engineered protease-resistant antibodies with selectable cell-killing functions.
    Kinder M, Greenplate AR, Grugan KD, Soring KL, Heeringa KA, McCarthy SG, Bannish G, Perpetua M, Lynch F, Jordan RE, Strohl WR, Brezski RJ.
    J Biol Chem; 2013 Oct 25; 288(43):30843-54. PubMed ID: 23986451
    [Abstract] [Full Text] [Related]

  • 15. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.
    Clynes RA, Towers TL, Presta LG, Ravetch JV.
    Nat Med; 2000 Apr 25; 6(4):443-6. PubMed ID: 10742152
    [Abstract] [Full Text] [Related]

  • 16. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.
    Tokuyama H, Hagi T, Mattarollo SR, Morley J, Wang Q, So HF, Moriyasu F, Nieda M, Nicol AJ.
    Int J Cancer; 2008 Jun 01; 122(11):2526-34. PubMed ID: 18307255
    [Abstract] [Full Text] [Related]

  • 17. Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer.
    Liikanen I, Tähtinen S, Guse K, Gutmann T, Savola P, Oksanen M, Kanerva A, Hemminki A.
    Mol Cancer Ther; 2016 Sep 01; 15(9):2259-69. PubMed ID: 27458139
    [Abstract] [Full Text] [Related]

  • 18. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R, Shimomura I, Konno S, Ito A, Masakari Y, Orimo R, Taki S, Arai K, Ogata H, Okada M, Furumoto S, Onitsuka M, Omasa T, Hayashi H, Katayose Y, Unno M, Kudo T, Umetsu M, Kumagai I.
    MAbs; 2014 Sep 01; 6(5):1243-54. PubMed ID: 25517309
    [Abstract] [Full Text] [Related]

  • 19. Tumor-associated hyaluronan limits efficacy of monoclonal antibody therapy.
    Singha NC, Nekoroski T, Zhao C, Symons R, Jiang P, Frost GI, Huang Z, Shepard HM.
    Mol Cancer Ther; 2015 Feb 01; 14(2):523-32. PubMed ID: 25512619
    [Abstract] [Full Text] [Related]

  • 20. Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.
    Li B, Xu L, Tao F, Xie K, Wu Z, Li Y, Li J, Chen K, Pi C, Mendelsohn A, Larrick JW, Gu H, Fang J.
    Oncotarget; 2017 Jun 13; 8(24):39356-39366. PubMed ID: 28454118
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.